Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Trigeminal neuralgia and its management

Open access
Bennetto, Luke, Patel, Nikunj K, Fuller, Geraint·2007·BMJ

Abstract

Objective: To assess the efficacy and safety of ocrelizumab over 3 years in patients with relapsing-remitting multiple sclerosis (RRMS) who rolled over from CASTING (NCT02861014) to LIBERTO (NCT03599245). Background: The Phase IIIb CASTING study evaluated the efficacy and safety of ocrelizumab in patients with RRMS with a suboptimal response to ≥6 months treatment with one or two prior disease-modifying therapies (DMTs). LIBERTO is a long-term extension study, in which eligible CASTING patients from participating countries could enroll. Design/Methods: Patients deemed by the treating neurologist as having a positive benefit-risk ratio at the end of the CASTING 96-week treatment period rolled over to LIBERTO and continued intravenous ocrelizumab 600mg every 24 weeks. Efficacy endpoints included no evidence of disease activity (NEDA; absence of protocol-defined relapses, 24-week confirmed disability progression, contrast-enhancing T1-weighted and new/enlarging T2-weighted lesions), with MRI rebaselining at CASTING Week 8. Safety outcomes included incidence/nature of adverse events (AEs). Results: As of October 12, 2020, 439/680 CASTING patients rolled over to LIBERTO. NEDA was observed in 82.6% of patients from baseline to Year 1 (n/N=549/665), 87.0% of patients from Year 1 to Year 2 (n/N=571/656) and 82.5% of patients from Year 2 to Year 3 (n/N=235/285). Over the 3-year period, 59.4% of patients had NEDA (n/N=190/320). Mean (SD) Expanded Disability Status Scale score was 2.09 (1.06) at CASTING baseline and 2.16 (1.48) at Year 3. Annualized relapse rate remained low (Year 1, 0.07; Year 2, 0.05; Year 3, 0.05). Overall, 92.3% of patients reported AEs (n/N=405/439) and 8.4% of patients reported serious AEs (n/N=37/439). Four patients from LIBERTO discontinued due to AEs (0.9%); one death occurred in CASTING. Conclusions: Patients with a suboptimal response to one or two prior DMTs who switched to ocrelizumab responded consistently well to ocrelizumab treatment over 3 years, based on clinical and MRI measures. No new safety signals were observed. Disclosure: Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for La revue des microbiotes. The institution of Patrick Vermersch has received research support from Roche. The institution of Patrick Vermersch has received research support from Sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for alexion. Prof. Van Wijmeersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Van Wijmeersch has received personal compensation in t

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.39085.614792.be

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 17 references

Cited by

See all 262

Metadata

Authors
Bennetto, L., Patel, N. K., & Fuller, G.
Venue
BMJ
Publisher
BMJ
Published
2007-01-25
Volume
334
Issue
7586
Pages
201-205
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2012945825
Cited by
262
References
17
FWCI
6.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trigeminal neuralgia and its management. https://app.cochat.ai/papers/10.1136/bmj.39085.614792.be
The paper
Bennetto, L., Patel, N. K., & Fuller, G. (2007). Trigeminal neuralgia and its management. BMJ. https://doi.org/10.1136/bmj.39085.614792.be

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.